Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 3, 2015 - Issue 1
Journal homepage
5,617
Views
84
CrossRef citations to date
0
Altmetric
Position Papers

Vaccination: the cornerstone of an efficient healthcare system

Vanessa RémySanofi Pasteur MSDLyon, FranceCorrespondence[email protected]
, PharmD, MSc,
York ZöllnerHamburg University of Applied SciencesHamburg, Germany
, PharmD, MSc, PhD &
Ulrike HeckmannSanofi Pasteur MSDBerlin, Germany
Article: 27041 | Received 18 Dec 2014, Accepted 13 May 2015, Published online: 12 Aug 2015

References

  • Global alliance for vaccines and immunization. 2011; World Health Organization – Media Center. Fact Sheet No. 169.
  • Ehreth J . The economics of vaccination from a global perspective: Present and future. 2–3 December, 2004, Vaccines: all things considered, San Francisco, CA, USA. Expert Rev Vaccines. 2005; 4(1): 19–21.
  • Garcia-Altes A . Systematic review of economic evaluation studies: Are vaccination programs efficient in Spain?. Vaccine. 2013; 31(13): 1656–65.
  • Ehreth J . The global value of vaccination. Vaccine. 2003; 21(7–8): 596–600.
  • OECD. Health at a glance 2013: OECD indicators 2011. Available from: http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf [cited 13 January 2015]..
  • De Melker HE. Seroepidemiology of diphtheria, tetanus, poliomyelitis and pertussis – Evaluation of the National Immunisation Programme in the Netherlands. 1999; Wageningen University, The Netherlands: PhD Thesis. Available from: http://www.narcis.nl/publication/RecordID/oai%3Alibrary.wur.nl%3Awurpubs%2F61043 [cited 12 December 2012]..
  • Farrant L . Vaccine infographic 2012. Available from: https://www.behance.net/gallery/2878481/Vaccine-Infographic [cited 12 December 2012]..
  • Roush SW , Murphy TV . Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007; 298(18): 2155–63.
  • Wicker S , Maltezou HC . Vaccine-preventable diseases in Europe: Where do we stand?. Expert Rev Vaccines. 2014; 13(8): 979–87.
  • van Panhuis WG , Grefenstette J , Jung SY , Chok NS , Cross A , Eng H et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med. 2013; 369(22): 2152–8.
  • World Health Organisation. WHO vaccine-preventable disease monitoring system, 2014 global summary. 2014. Available from: http://apps.who.int/immunization_monitoring/globalsummary [cited 28 November 2014]..
  • World Health Organisation. The global burden of disease: 2004 update 2004. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1 [cited 9 December 2014]..
  • Ehreth J . The value of vaccination: A global perspective. Vaccine. 2003; 21(27–30): 4105–17.
  • Lieu TA , McGuire TG , Hinman AR . Overcoming economic barriers to the optimal use of vaccines. Health Aff (Millwood). 2005; 24(3): 666–79.
  • Zhou F , Shefer A , Wenger J , Messonnier M , Wang LY , Lopez A et al. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics. 2014; 133(4): 577–85.
  • Ekwueme DU , Strebel PM , Hadler SC , Meltzer MI , Allen JW , Livengood JR . Economic evaluation of use of diphtheria, tetanus, and acellular pertuss is vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med. 2000; 154(8): 797–803.
  • Thompson KM , Tebbens RJ . Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal. 2006; 26(6): 1423–40.
  • Scuffham PA , West PA . Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine. 2002; 20(19–20): 2562–78.
  • Boccalini S , Taddei C , Ceccherini V , Bechini A , Levi M , Bartolozzi D et al. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: An a posteriori evaluation and forecast of future benefits. Hum Vaccin Immunother. 2013; 9(5): 1119–28.
  • Barrett S . Eradication versus control: The economics of global infectious disease policies. Bull World Health Organ. 2004; 82(9): 683–8.
  • OECD. Health at a glance 2011: OECD indicators 2011. Available from: http://www.oecd.org/els/health-systems/49105858.pdf [cited 9 December 2014]..
  • Barnighausen T , Bloom DE , Cafiero ET , O'Brien JC . Economic evaluation of vaccination: Capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infect. 2012; 18(Suppl 5): 70–6.
  • Szucs T , Quilici S , Panfilo M . From population to public institutions: What needs to be changed to benefit from the full value of vaccination. J Market Access Health Policy. 2015; 3 26965, doi: http://dx.doi.org/10.3402/jmahp.v3.26965 .
  • Drummond M . NICE: A nightmare worth having?. Health Econ Policy Law. 2007; 2(Pt 2): 203–8. [PubMed Abstract] discussion 17–21.
  • Koleva D , De Compadri P , Padula A , Garattini L . Economic evaluation of human papilloma virus vaccination in the European Union: A critical review. Intern Emerg Med. 2011; 6(2): 163–74.
  • Szucs TD , Pfeil AM . A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013; 31(2): 125–36.
  • Aballea S , Millier A , Quilici S , Caroll S , Petrou S , Toumi M . A critical literature review of health economic evaluations of rotavirus vaccination. Hum Vaccin Immunother. 2013; 9(6): 1272–88.
  • CDC. Vaccines & immunizations: possible side-effects from vaccines 2015. Available from: http://www.cdc.gov/vaccines/vac-gen/side-effects.htm [cited 11 May 2015]..

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.